Dr Peyvand Khaleghian

Managing Partner, Avicenna Partners Investment Company LLC, United Arab Emirates

 



Dr Peyvand Khaleghian is a Managing Partner at Avicenna Partners Investment Company LLC, an emerging markets-focused healthcare investment firm based in the United Arab Emirates, and co-Founder and Director of Amana Healthcare, the largest and fastest-growing provider of specialized long-term acute care, post-acute rehabilitation and home transition and respite care services in the Middle East. He also serves as a member of the Business Advisory Council of the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Health System in Washington DC.

Dr Khaleghian started his career as a physician but later spent eight years as a senior healthcare specialist at the World Bank – four of them as Sector Leader in its Europe and Central Asia healthcare practice based in Almaty, Kazakhstan – with a further three years as Director of Health Policy and Strategy for the Government of Dubai.

A New Zealand national, Dr Khaleghian holds a doctorate in Health Policy and Management from the Johns Hopkins University and a medical degree from the University of Auckland.

Promoting an Innovation Culture in Hospitals – Concepts and Experience 

Hospitals can play an important role in the development, demonstration and deployment of healthcare technology. This presentation reviews concepts and experience at the interface between technology innovators and front-line hospitals clinicians and how the two can work together effectively at various stages of the technology development process without compromising patient safety, clinical effectiveness or ethical standards. The role of formal institutional arrangements such as technology transfer offices/departments is discussed together with options for independent innovators seeking to establish productive collaboration with hospital-based clinicians. 

Going Global – Challenges in Emerging Markets 

Healthcare in emerging markets is booming. As incomes rise and populations age, the demand for healthcare products, services and technologies increases, creating opportunities for healthcare companies across the board, especially those from mature markets. But how are emerging markets different from mature ones? The opportunity is clear—but what about the risks? This presentation discusses some of the peculiarities of emerging healthcare markets and the challenges healthcare companies can expect to face in entering them. Emerging and mature markets are contrasted in terms of governance, market and competitor behaviour, regulatory ambiguity and volatility, and consumer behaviour, among others.